LHCG - HCA Healthcare downgraded despite strong Q1 results LHC Group becomes a new catalyst call; and more in today's analyst action

The anticipated impact on healthcare in a post-pandemic setup has led to contrasting views on two different healthcare providers: HCA Healthcare and LHC Group. Furthermore, several initiations are also included in today’s analyst action.HCA Healthcare downgraded at CitiCiti analysts Ralph Giacobbe and Jason Cassorla have downgraded HCA Healthcare (HCA) to neutral from buy.However, noting its solid Q1 2020 results posted they have raised the price target to $215.00 from $191.00 per share indicating a ~6.2% upside to the last close. HCA is trading ~0.7% lower in the pre-market.With a ~93.3% gain in HCA shares over the past 12-month period, the analysts see a balanced risk-reward at the current valuation as they anticipate lower contributions from future COVID-related admissions.At HCA, the percentage of COVID-19 admits to total admits has declined throughout the quarter, Sam Hazen, the company CEO revealed on the Q1 2020 earnings call.LHC Group generates a new catalyst call at Deutsche BankDeutsche Bank has opened

For further details see:

HCA Healthcare downgraded despite strong Q1 results, LHC Group becomes a new catalyst call; and more in today’s analyst action